This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
by Zacks Equity Research
United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -1.67% move from the previous day.
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -0.78% move from the previous day.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.
Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Actinium Pharmaceuticals, Inc. (ATNM).
Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Actinium Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval
by Zacks Equity Research
FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.
Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.
How Actinium Pharmaceuticals (ATNM) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed at $0.24 in the latest trading session, marking a +1.04% move from the prior day.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $0.26, moving -0.54% from the previous trading session.
Actinium (ATNM) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.